DrugPatentWatch Database Preview

Details for Patent: 7,198,801

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 7,198,801 protect, and when does it expire?

Patent 7,198,801 protects ELESTRIN and GELNIQUE 3% and is included in two NDAs.

This patent has fifty-five patent family members in twenty countries.

Summary for Patent: 7,198,801

Title:	Formulations for transdermal or transmucosal application
Abstract:	The present invention relates generally to formulations for transdermal or transmucosal administration of an active agent. The invention is a substantially malodorous-free and irritation free transdermal formulation which is substantially free of long chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters.
Inventor(s):	Carrara; Dario Norberto R. (Oberwil, CH), Grenier; Arnaud (Steinbrunn le Haut, FR), Besse; Celine (Saint Louis, FR), Simes; Stephen M. (Long Grove, IL), Lehman; Leah M. (Green Oaks, IL)
Assignee:	Antares Pharma IPL AG (Zug, CH)
Application Number:	10/798,161
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,198,801
Patent Claim Types: see list of patent claims	Formulation; Compound; Delivery;

Drugs Protected by US Patent 7,198,801

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Mylan Speciality Lp	ELESTRIN	estradiol	GEL, METERED;TRANSDERMAL	021813-001	Dec 15, 2006		RX	Yes	Yes			Y
Allergan	GELNIQUE 3%	oxybutynin	GEL, METERED;TRANSDERMAL	202513-001	Dec 7, 2011		DISCN	Yes	No			Y

Foreign Priority and PCT Information for Patent: 7,198,801

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	PCT/EP00/07533	Aug 03, 2000

International Family Members for US Patent 7,198,801

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	030312
Austria	355854
Austria	356636